Leading Justice is a full-service marketing company working with law firms on a cash buy basis to sign up fully-qualified, fraud-free Actemra cases. Here at Leading Justice, we can customize your firm’s Actemra advertising needs and help you sign up cases via internal cash buys. Our clients simply pay an agency fee to cover the cost of Actemra advertising, plus a fee for each case we sign, and any data we generate for your firm belongs to you. We also cross-qualify all of our contacts, which means any data we generate that doesn’t qualify for the target campaign is reviewed to determine whether it is eligible for another type of claim. By using advanced approaches to target contacts specifically related to Actemra use and side effects like heart attack, heart disease and pancreatitis, Leading Justice will increase your firm’s Actemra caseload. If you are interested in helping victims of alleged Actemra side effects, our direct advertising strategies and extensive consumer reach give you the competitive edge and confidence to allocate your full budget, knowing your money is being used in the best way possible.
Each and every law firm we work with at Leading Justice plays an important role in determining how we classify claims as qualified or not. While our experience working with plaintiff law firms helps us recognize a great case when we see one, we will tailor our Actemra case intake specifications to the exact criteria you are seeking. So, if your firm has specific Actemra qualifying case criteria you would like us to use, we can train our intake specialists to apply the criteria to each email and phone call they receive. By eliminating the middle man, Leading Justice offers clients an opportunity for internal cash buys of Actemra data with zero chance of fraud.
Actemra Side Effect Litigation
Actemra (tocilizumab) is a blockbuster prescription medication that relieves joint pain associated with rheumatoid arthritis (RA). Taken intravenously or by injection, Actemra works by inhibiting parts of the immune system that cause inflammation, a hallmark of the autoimmune disease. When Actemra first entered the market in 2010, it was touted by Roche Holding AG as a superior alternative to other rheumatoid arthritis medications, like Humira, Enbrel and Remicade, many of which carry warnings regarding their potential for causing serious cardiovascular problems and other side effects in users. According to a growing body of research, Roche’s Actemra treatment may actually pose a risk of heart-related complications and other adverse events that is as high or even higher than its competitors.
A number of studies and adverse event reports submitted to the FDA by Actemra users have identified a risk of serious side effects potentially linked to the rheumatoid arthritis drug, which has been associated with at least 13,500 reports of health problems and at least 1,128 deaths since 2010. Yet, federal regulators have failed to require new warnings on the Actemra label notifying users about the potential for the rheumatoid arthritis treatment to cause heart attack, heart failure, interstitial lung disease and other side effects that may be life-threatening. As more information comes to light about the serious health risks associated with Actemra, which is prescribed to treat RA and, off-label, up to 60 other conditions, Actemra injury lawsuits are expected to be filed against Roche in the coming months and years.